Huntington National Bank Biocryst Pharmaceuticals Inc Transaction History

Huntington National Bank

$13.5 Billion
Q3 2024

A detailed history of Huntington National Bank transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Huntington National Bank holds 6,741 shares of BCRX stock, worth $50,490. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,741

Previous 6,688 0.79%

Holding current value

$50,490

Previous $41,000 24.39%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	BUY	$6.41 - $8.69 $339 - $460	53 Added 0.79%	6,741 $51,000
Q2 2024 Aug 08, 2024	SELL	$4.13 - $6.79 $103 - $169	-25 Reduced 0.37%	6,688 $41,000
Q1 2024 May 03, 2024	SELL	$4.89 - $7.65 $738 - $1,155	-151 Reduced 2.2%	6,713 $34,000
Q4 2023 Feb 07, 2024	BUY	$4.98 - $6.77 $59 - $81	12 Added 0.18%	6,864 $41,000
Q3 2023 Nov 08, 2023	SELL	$6.71 - $7.92 $952 - $1,124	-142 Reduced 2.03%	6,852 $48,000
Q2 2023 Aug 11, 2023	BUY	$6.96 - $8.81 $2,164 - $2,739	311 Added 4.65%	6,994 $49,000
Q1 2023 May 10, 2023	BUY	$7.94 - $11.84 $9,051 - $13,497	1,140 Added 20.57%	6,683 $55,000
Q4 2022 Feb 09, 2023	SELL	$10.5 - $14.2 $409 - $553	-39 Reduced 0.7%	5,543 $63,000
Q3 2022 Nov 07, 2022	BUY	$10.79 - $14.81 $11,663 - $16,009	1,081 Added 24.02%	5,582 $70,000
Q2 2019 Jul 23, 2019	BUY	$2.91 - $9.15 $2 - $9	1 Added 0.02%	4,501 $17,000
Q1 2019 Apr 09, 2019	SELL	$7.38 - $9.72 $7 - $9	-1 Reduced 0.02%	4,500 $37,000
Q3 2018 Oct 18, 2018	BUY	$5.52 - $7.99 $5 - $7	1 Added 0.02%	4,501 $34,000
Q2 2018 Jul 19, 2018	BUY	$4.6 - $6.52 $20,700 - $29,339	4,500 New	4,500 $26,000

Others Institutions Holding BCRX

# of Institutions

280

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Huntington National Bank with notifications on news.

Account

Huntington National Bank Biocryst Pharmaceuticals Inc Transaction History